Pharmaceuticals, Biotechnology and Life Sciences
Don't spend too much on your repeated translations.
Cut costs with Vikler Media. Visit: media.vikler.net
Secarna to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases.
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will be focused on developing new therapies for autoimmune diseases that...
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast density this Christmas. Dense breast tissue is a relatively unknown but common breast cancer risk factor, which additionally makes it...
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...
Over-65s across the UK are set to benefit from potentially life-changing new treatment options for conditions like cancer and cardiovascular...
SteQeyma™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration…
San Diego, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) — Sapu BioScience today announced the publication of a new peer-reviewed study…
HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) — Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ: HKPD) (“HKPD” or the…
Novel treatment for PSVT developed with Milestone Pharmaceuticals CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–Aptar Group, Inc. (NYSE: ATR), a global leader in…
DUBLIN–(BUSINESS WIRE)–The “Malabsorption Syndrome Market – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market for…
DUBLIN–(BUSINESS WIRE)–The “Constipation Treatment – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market for Constipation…
Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved for eligible…
SEATTLE & TOKYO–(BUSINESS WIRE)–Talus Bioscience, Inc. (“Talus Bio”), an AI-enabled regulome therapeutics company, today announced a strategic collaboration with PRISM…
DUBLIN–(BUSINESS WIRE)–The “Short Bowel Syndrome (SBS) – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market…
DUBLIN–(BUSINESS WIRE)–The “Drug Discount Cards Market – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market…
